Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma (scientific article published on 31 May 2012)

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Q33340726

Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial

Q33364465

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation

Q33448095

A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity.

Q33497855

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

Q33795058

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

Q34195428

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

Q34753416

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

Q35606328

A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97

Q37088191

Current status of autologous hematopoietic stem cell transplantation in myeloma

Q37251047

Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).

Q37280737

The current status and future of multiple myeloma in the clinic

Q37707682

New developments in conditioning regimens before auto-SCT in multiple myeloma

Q37848037

Kinetics of intravenous melphalan

Q38537678

Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.

Q43405306

Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma

Q44492261

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

Q44937084

BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma

Q46127672

High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study

Q46648237

Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases

Q48406543

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.

Q50565712

A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.

Q50853259

P433

issue

P304

page(s)

145-150

P577

publication date

2012-05-31

P1433